The in vitro and in vivo evaluation of ddC as a topical antiviral for ocular adenovirus infections

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 11, 2009, Pages 5295-5299

  Romanowski, Eric G ^a   Yates, Kathleen A ^a   Gordon, Y Jerold ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; ZALCITABINE;

ADENOVIRUS INFECTION; ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; EXPERIMENTAL RABBIT; EYE INFECTION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; SCAR FORMATION; SEROTYPE; VIRUS ISOLATION; VIRUS TITRATION;

ADENOVIRIDAE INFECTIONS; ADENOVIRUSES, HUMAN; ADMINISTRATION, TOPICAL; ANIMALS; ANTIVIRAL AGENTS; CONJUNCTIVITIS, VIRAL; CYTOSINE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; PHOSPHONIC ACIDS; PLAQUE ASSAY; RABBITS; TUMOR CELLS, CULTURED; VIRUS REPLICATION; ZALCITABINE;

EID: 78649430193     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-3286     Document Type: Article

References (27)

1. Gordon JS, Aoki K, Kinchington PR. Adenovirus keratoconjunctivitis. In: Pepose JS, Holland GN, Wilhelmus KR, eds. Ocular Infection and Immunity. St Louis: Mosby; 1996;877-894.
2. Gordon YJ, Romanowski EG, Araullo-Cruz T, De Clercq E. Pre-treatment with topical 0.1% S-HPMPC inhibits adenovirus type 5 replication in the NZ rabbit ocular model. Cornea. 1992;11:529-533.
3. Gordon YJ, Romanowski EG, Araullo-Cruz T. Topical HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model. Invest Ophthalmol Vis Sci. 1994;35:4135-4143.
4. Romanowski EG, Gordon YJ. Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model. Invest Ophthalmol Vis Sci. 2000;41:460-463.
5. Romanowski EG, Yates KA, Gordon YJ. Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/New Zealand rabbit ocular model. Antiviral Res. 2001;52:275-280.
6. Gordon, YJ. Adenovirus pathogenesis and therapy. Abstracts of the Second International Conference on Ocular Infections. August 22, 1998. Munich, Germany. 1998;5.
7. Romanowski EG, Gordon YJ, Araullo-Cruz T, Yates KA, Kinchington PR. The antiviral resistance and replication of cidofovir-resistant adenovirus variants in the New Zealand white rabbit ocular model. Invest Ophthalmol Vis Sci. 2001;42:1812-1815.
8. Romanowski EG, Yates KA, Teuchner B, Nagl M, Irschick EU, Gordon YJ. N-chlorotaurine is an effective antiviral agent against adenovirus in vitro and in the Ad5/NZW rabbit ocular model. Invest Ophthalmol Vis Sci. 2006;47:2021-2026.
9. Nwanegbo EC, Romanowski EG, Gordon YJ, Gambotto A. Efficacy of topical immunoglobulins (IG) against experimental adenoviral ocular infection. Invest Ophthalmol Vis Sci. 2007;48:4171-4176.
10. Van der Vliet PC, Kwant MM. Role of DNA polymerase g in adenovirus DNA replication: mechanism of inhibition by 2',2'-dideoxynucleoside 5'-triphosphates. Biochemistry. 1981;20:2628-2632.
11. Mentel R, Kinder M, Wegner U, von Janta-Lipinski M, Matthes E. Inhibitory activity of 3'-fluoro-2' deoxythymidine and related nucleoside analogues against adenoviruses in vitro. Antiviral Res. 1997;34:113-119.
12. Mentel R, Wegner U. Evaluation of the efficacy of 2',3'-dideoxycytidine against adenovirus infection in a mouse pneumonia model. Antivir Res. 2000;47:79-87.
13. Eiichi U, Fuchigami A, Kadonosono K, et al. Anti-adenoviral effect of anti-HIV agents in vitro in serotypes inducing keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol. 2007;245:1319-1325.
14. Gordon YJ, Araullo-Cruz T, Romanowski EG. An ocular model of adenovirus type 5 infection in the NZ rabbit. Invest Ophthalmol Vis Sci. 1992;33:574-580.
15. Romanowski EG, Roba LA, Wiley LA, Araullo-Cruz T, Gordon YJ. The effects of corticosteroids on adenoviral replication. Arch Ophthalmol. 1996;114:581-585.
16. Gordon YJ, Araullo-Cruz T, Romanowski EG. The effects of topical NSAIDS on adenoviral replication. Arch Ophthalmol. 1998;116: 900-905.
17. Romanowski EG, Pless P, Yates KA, Gordon YJ. Topical cyclosporine A inhibits subepithelial immune infiltrates but also promotes viral shedding in experimental adenovirus models. Cornea. 2005; 24:86-91.
18. Romanowski EG, Gordon YJ. Progress against adenoviral conjunctivitis. Am J Ophthalmol. 2008;146:635-637.
19. Nagl M, Larcher C, Gottardi W. Activity of N-chlorotaurine against herpes simplex- and adenoviruses. Antiviral Res. 1998;38:25-30.
20. Teuchner B, Nagl M, Schidlbauer A, et al. Tolerability and efficacy of N-chlorotaurine in epidemic keratoconjunctivitis: a doubleblind, randomized, phase-2 clinical trial. J Ocul Pharmacol Ther. 2005;21:157-165.
21. Epstein SP, Pashinsky YY, Gershon D, et al. Efficacy of topical cobalt chelate CTC-96 against adenovirus in a cell culture model and against adenovirus keratoconjunctivitis in a rabbit model. BMC Ophthalmol. 2006;6:22.
22. Asbell PA, Epstein SP, Wallace JA, et al. Efficacy of cobalt chelates in the rabbit eye model for epithelial herpetic keratitis. Cornea. 1998;17:550-557.
23. Hartley C, Hartley M, Pardoe I, Knight A. Ionic contra-viral therapy (ICVT): a new approach to the treatment of DNA virus infections. Arch Virol. 2006;151:2495-2501.
24. De Clercq E, Murase J, Marquez VE. Broad-spectrum antiviral and cytocidal activity of cyclopentenylcytosine, a carbocyclic nucleoside targeted at CTP synthetase. Biochem Pharmacol. 1991;41: 1821-1829.
25. Marquez VE, Lim MI, Treanor SP, et al. Cyclopentenylcytosine: a carbocyclic nucleoside with antitumor and antiviral properties. J Med Chem. 1988;31:1687-1694.
26. Blum AS, Dal Pan GJ, Feinberg J, et al. Low-dose zalcitabine-related toxic neuropathy: frequency, natural history, and risk factors. Neurology. 1996;46:999-1003.
27. HIVID (zalcitabine) Tablets. Complete Product Information. http://www.rocheusa.com/products/hivid/pi.pdf. Indianapolis, IN; Roche; 2002.